CD274 and neoplasm: We hypothesize that patients who received immune checkpoint inhibitors were likely prescribed treatment based on biomarkers, exhibiting tumor characteristics such as dMMR/MSI-H or PD-L1 positivity, and that these biomarkers may have contributed to a favorable response to treatment across cohorts.